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Abstract
In non-endemic countries, acute (invasive) schistosomiasis (AS) is typically seen in non-immune travellers, whereas chronic schistosomia-
sis is more frequently diagnosed in immigrants. Travellers with AS initially present with non-speciﬁc signs such as fever, cough, head-
ache, and urticaria. Life-threatening cardiac and neurological complications may occur. The positive diagnosis of AS relies on
seroconversion, which appears together with hypereosinophilia approximately 3 weeks after the onset of symptoms. When prescribed
during AS, praziquantel usually does not prevent the chronic phase of the disease and is associated with exacerbation of signs and symp-
toms in approximately 50% of cases. According to the published literature, corticosteroids may be recommended alone or in associa-
tion with praziquantel. When associated with corticosteroids, pharmacokinetic interactions may impair the efﬁcacy of praziquantel. We
suggest that corticosteroids should be restricted to use in patients with systemic complications of AS, whereas praziquantel should be
initiated only when ova are detected in either stools or urine, depending on the culprit species.
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Acute schistosomiasis (also called Katayama fever or syn-
drome) is one of the clinical manifestations of infection with
Schistosoma sp. [1]. It occurs several weeks after the penetra-
tion of schistosome cercariae through the skin, and is related
to the migration of the larvae (schistosomulae) within the
body. Oviposition, which deﬁnes the chronic phase of the
disease, typically occurs weeks later. This symptomatic acute
phase is mostly described in non-immune individuals (i.e.
tourists) exposed to fresh water in endemic areas (Fig. 1)
[1–3].
Acute schistosomiasis (AS) appears to be a more appropri-
ate term than ‘Katayama fever’ for this disease. Katayama
fever was described in 1847 in the Katayama district of Japan,
and has been known to be caused by Schistosoma japonicum
since 1904 [4,5]. It is of note that there is no longer schistoso-
miasis in the Katayama district as there is in the rest of Japan.
In addition, all species of human schistosome can lead to AS in
infected humans. There is thus no reason to use a name refer-
ring to S. japonicum or Japan in order to describe this disease.
Finally, as fever is not always present in AS, the use of ‘fever’
in referring to the disease is not clinically relevant.
The recent report of a large series and clusters of AS in
travellers with a single exposure allows us to better describe
its natural history, pathophysiology, presentation, complica-
tions, diagnosis, and treatment.
Epidemiology
In Europe, the Geosentinel Surveillance network reported
401 cases of travel-associated schistosomiasis seen within
11 years (1997–2008) in 27 sites in 12 Western countries,
without making a distinction between acute and chronic
schistosomiasis [6]. In two European series of 257 and 1640
febrile travellers returning from abroad, AS was diagnosed in
1.6% and 1.7% of travellers, respectively [7,8]. In one of
these series, AS was the third most common cause of febrile
diseases imported from Africa, after malarial and rickettsial
infections [8]. In France, a retrospective study conducted
between 2000 and 2004 in 42 parasitology laboratories
found that 77 patients were diagnosed with AS [9]. AS usu-
ally occurs sporadically or as small outbreaks [10,11].
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Most cases of imported AS are described in travellers
returning from West and East African countries such as Mali
(Dogon country), Burkina Faso (Banfora falls), Ethiopia
(National Park of Omo), Malawi Lake, and Zambia (Zambese
Falls), from Brazil, and also from Laos [8,11–22]. Attack rates
during outbreaks in tourists exposed while swimming in con-
taminated water vary from 39% [23] to 100%, but are usually
above 65% [3,12,19].
One study showed relationships between the number of
exposures, the duration of exposure and the risk of infection
[24]. Overall, infection is symptomatic in 54–100% of the
non-immune infected travellers (Table 1). During the last two
decades, AS has been more often reported in travellers
infected with Schistosoma mansoni or Schistosoma haematobium
than in those infected with S. japonicum or S. mekongi [6,9].
Pathophysiology
Acute schistosomiasis is considered to be a toxaemic and
allergic reaction to the migrating and maturing larvae of Schis-
tosoma [1,25]. The severity of the clinical presentation varies
according to the cercarial burden and the immune response
to the released parasite antigens [26]. Dry cough and angio-
oedema, together with high counts of eosinophils, point to a
type 1 hypersensitivity reaction.
FIG. 1. Global distribution of schistosomiasis, adapted from Gryseels and Doumenge [2].
TABLE 1. Summary of reports of outbreaks of acute schistosomiasis (involving at least ten patients) among travellers
Reference [13] [33] [15] [14] [12] [16] [17] [17] [18] [21] [11] [24]
Year 1995 1995 1996 1996 1998 1998 2001 2001 2002 2003 2003 2008
Exposed persons 29 13 12 16 10 29 13 13 31 18 18 27
Attack rate (%) 96 62 92 100 100 69 92 100 100 94 100 81
Country of infection Mali Mali Burkina
Faso
Malawi
Mozambique
Ghana Burkina
Faso
Brazil Brazil Brazil Brazil Mali Tanzania
Culprit species Sh, Sm, Si Sm Sm Sh Sm Sm Sm Sm Sm Sm Sh Sm
History of CD (%) 36 62.5 NA 13 20 5 100 NA NA 100 94 13.6
Incubation period 2–10
weeks
NA 3–6
weeks
36
days
2–5
weeks
27
days
2–4
weeks
20
days
3–4
weeks
32
days
19
days
3–13
weeks
Acute schistosomiasis
(%)
54 54 54 100 80 70 91 92 100 100 77 86
CD, cercarial dermatitis (swimmer’s itch); NA, not available; Sm, Schistosoma mansoni; Sh, Schistosoma haematobium; Si, Schistosoma intercalatum.
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Circulating immune complexes are found in c. 55–93% of
patients with AS, and their presence is correlated with the
intensity and severity of symptoms [27,28]. Moreover, direct
toxicity of eosinophils seems also to play an important role
[29]. High counts of eosinophils are found during severe
forms of AS. Major basic protein and eosinophil cationic pro-
tein, found in the eosinophil granules, are released during cell
activation and could contribute to the severity of the disease
by their direct toxicity, affecting vessels of the heart and brain
[29,30]. A particular cytokine pattern, with high levels of pro-
inﬂammatory cytokines (interleukin (IL)-1, IL-6, and tumour
necrosis factor-a) and a poor Th2-type response (IL-4 and
IL-5), has been described during AS. This cytokine pattern
could explain the altered general status seen during AS [18].
These symptoms are typically seen before oviposition,
egg-laying, and the appearance of granulomatous reactions
around eggs, which deﬁnes the chronic phase of the disease.
However, the two phases of the cycle may overlap, because
an individual schistosomula may make several circuits in the
pulmonary and systemic circulation before ﬁnding its way to
the hepatic portal system [31]. This explains why the delay
between skin penetration of the cercariae and egg-laying may
vary from one study to another. This is also illustrated by
some studies that found eggs in stool or urine although
some symptoms of AS were still present [8].
Clinical Presentation
The most common signs of AS are fever, dry cough, weak-
ness, headache, abdominal symptoms, and urticaria or angio-
oedema (Fig. 2).
A history of exposure to contaminated water in endemic
areas is essential. The disease is usually acquired while people
are bathing in fresh water and, to a lesser extent, when they
are crossing rivers or showering with contaminated water
[9]. Contact as brief as 1–5 min may be enough to allow
transcutaneous penetration by cercariae [32,33]. A diffuse
maculopapular pruritic skin eruption, named cercarial derma-
titis, appears within 24 h after exposure. Pruritus alone may
be the only sign [13]. The eruption lasts for a few hours
before disappearing spontaneously [1,34]. Therefore, a his-
tory of such an eruption can be found upon questioning, but
it is rarely noticeable on the skin of returning travellers [25].
Reports of outbreaks in travellers with a single exposure
have contributed to a better description of the natural his-
tory of schistosomiasis (Table 1). Cercarial dermatitis is
reported in 5–100% of exposed travellers. The ﬁrst symp-
toms of AS usually occur 2–6 weeks after exposure
[11,14,25]. However, incubation periods from 1 to 12 weeks
have been reported [8,13,35]. The main signs and symptoms
are fever, cough, headaches and urticaria, but these may vary
according to the infecting Schistosoma species (Table 2).
Fever is frequent but usually mild. Fever above 39C is seen
in approximately one-third of cases [8], and appears approxi-
mately 19 days after exposure [11].
Nonetheless, this phase of schistosomiasis may be unap-
parent. Among 137 cases of schistosomiasis acquired during
travel, clinical ﬁndings compatible with AS were found in 75
patients (66%). Thus, more than one-third of infected
patients may have no signs of AS [36]. As a consequence,
individuals exposed to contaminated water should be investi-
gated for schistosomiasis even in the absence of symptoms.
Life-threatening Complications
Neurological, pulmonary and cardiac complications can occur
during AS, and some may be life-threatening. Neurological
manifestations have been observed in c. 2% of cases of AS in
the largest series conducted so far, during the Philippines
FIG. 2. Acute urticaria during acute (invasive) schistosomiasis.
TABLE 2. Major signs and symptoms observed during acute
schistosomiasis according to the culprit species of Schistosoma
Signs and
symptoms (%)
Schistosoma
mansoni
95 patients
[12,15–18]
Schistosoma
haematobium
34 patients
[11,14]
Fever 54–100 93–94
Abdominal pain 33–93 0
Dry cough 17–91 44–86
Headache 33–87 31–93
Diarrhoea 25–81 14
Liver enlargement 17–75 0–25
Myalgias 50–74 14–69
Neck pain 64 71
Urticaria 8–17 13–57
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campaign of 1944–1945 during World War II [37]. Of the
1200 US soldiers infected with S. japonicum, 27 presented
with neurological involvement during AS. Headache, distur-
bances of sensorium and weakness were all present, and
c. 84% of the patients were febrile at one time or another;
44% presented with transient hemiplegia or tetraplegia; 60%
complained of visual impairment; and 50% complained of
incontinence, speech impairment, or ataxia. Neurological
manifestations have also been described in travellers with AS
caused by S. mansoni or S. haematobium infection [29,38].
The brain involvement during AS may be perceived as head-
ache, confusion, seizures, loss of consciousness, focal deﬁ-
ciencies, visual impairment, ataxia, urinary incontinence, or
motor paralysis [29,37,39–43]. In one of these cases, mag-
netic resonance imaging showed border-zone infarcts sugges-
tive of cerebral vasculitis [29].
Cardiac injuries such as myocarditis, pericarditis or asymp-
tomatic myocardial ischaemia have also been described dur-
ing AS [29,44,45]. As was the case for neurological
complications, the ﬁrst description of cardiac complications
was made during the Leyte campaign [46]. An analysis of 315
electrocardiograms revealed various repolarization abnormal-
ities: anomalies of T-waves (99%) or ST segments (52%). In
addition, cardiac involvement has been described during an
outbreak in Brazil [18]. Among the 31 patients infected with
S. mansoni, 12 (38.7%) had chest pain and six (19%) had a
positive ultrasound diagnosis of pericarditis.
Pulmonary complications of AS are better described
[47,48]. In a series of ten patients with AS, systematic chest
computed tomography scan showed pulmonary nodules
ranging in size from 2 to 15 mm, even in the absence of
associated respiratory symptoms in as many as four patients
[47]. When patients have respiratory symptoms, chest
X-rays show ill-deﬁned pulmonary nodules. Pulmonary
symptoms and radiographic abnormalities point to interstitial
pneumonitis, similar to what is seen in tropical pulmonary
eosinophilia. It is noteworthy that these severe forms can
occur either during spontaneous evolution of the disease or
after treatment with praziquantel [11,29,45,49].
Diagnosis
Eosinophilia
The eosinophil count is usually above normal limits during
AS. The onset of eosinophilia is delayed as compared with
the onset of symptoms. Among 13 patients with AS, the
mean delay between onset of fever and occurrence of hyper-
eosinophilia was 21 days, whereas the delay between con-
taminating bathing and occurrence of hypereosinophilia was
47 days (range: 25–119 days) [11]. In another series of 42
cases of AS, the eosinophil count was within normal limits in
27% [36]. Therefore, the absence of eosinophilia does not
rule out the diagnosis of AS.
Stool and urine analysis
Ova production begins at the end of adult maturation and
migration to the vesical plexus or mesenteric veins, depend-
ing on the Schistosoma species, with at least 30–50 days from
skin penetration to egg-laying [31]. In the early stages of AS,
a search for ova in stools or urine is typically negative, and
will remain so until the end of the entire life cycle. Nonethe-
less, ova may still be detected in the urine or stools of
patients complaining of symptoms compatible with AS. For
example, among 23 patients with signs of AS, a search for
ova in stools or urine at ﬁrst investigation was positive in
ﬁve (22%), laboratory examination being performed within
3 weeks of onset of fever [8]. Overall, the period of egg
detection varies from 5 to 10 weeks after exposure. More-
over, early treatment with praziquantel can delay egg-laying,
as suggested by one study in which the mean delay between
exposure and detection of ova was 196 days (range: 124–
330 days) [11].
Serodiagnosis
The diagnosis of AS relies on serological testing. Nonethe-
less, there are three things to keep in mind. First, serological
ﬁndings are usually negative at the onset of clinical signs, and
serological investigations must be repeated to identify sero-
conversion, which may appear up to 3 weeks (mean interval:
26 days) after the onset of symptoms, and c. 6 weeks (range:
27–100 days) after contact with contaminated water [11,25].
Therefore, upon primary investigation by a physician, sero-
logical ﬁndings are positive in no more than 65% of the cases
[8,11].
Second, the sensitivity and speciﬁcity of serological tests
vary with the antigens used; the tests are not uniform
throughout the world; and most of the tests can be per-
formed only in research laboratories. ELISA usually makes
use of egg antigens (Schistosoma Egg Antigen/ELISA). It is
indicated for the detection of schistosomiasis; however, sen-
sitivity is no more than 50% [1,50]. Enzyme-linked immuno-
transfer blot is used for conﬁrmation in the case of a
positive ELISA result. This test is considered to be 100% spe-
ciﬁc, and results are usually available 4–6 weeks after expo-
sure [51]. When worm antigens are used, as in indirect
haemagglutination tests, sensitivity reaches 70–90% for the
diagnosis of AS according to the cut-off titre deﬁning positiv-
ity [50]. A combination of both ELISA and indirect haemag-
glutination gives 90% sensitivity and 92.9% speciﬁcity [50].
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Moreover, infecting species identiﬁcation cannot be per-
formed with serological testing. For example, in one series
of 22 patients infected with S. mansoni, serological cross-
reactivity to S. haematobium was found in three patients,
whereas only one patient was formally diagnosed as having
S. mansoni by identiﬁcation of ova in stool [24]. According to
outbreak reports, seroconversion and ova production may
appear up to 6 months and 330 days after exposure, respec-
tively [11,14].
ALAT rate is increased in c. 40–50% of cases, but to no
more than ﬁve times above the normal upper limit [11,17].
Thrombocytopenia is seen in c. 10% of cases.
Treatment
Corticosteroid treatment better than praziquantel
treatment?
Treatment of AS is a real challenge, given that the efﬁcacy of
drugs varies according to the age of the schistosomulae [52–
54]. Usually, the recommended dosage of praziquantel for
chronic infection with S. mansoni or S. haematobium is 40 mg/
kg once daily. Nonetheless, praziquantel is not effective dur-
ing AS, and is sometimes associated with severe reactions
[29,33,38,55]. It is ineffective on schistosomulae above 7 days
of age [52,53], and does not prevent the chronic phase of
the disease [11,36]. Indeed, in a series of 18 travellers, treat-
ment with praziquantel during the incubation and acute
phase of schistosomiasis was unable to prevent egg-laying
and progression to a chronic stage [11]. Furthermore, early
treatment can worsen the symptoms of AS by inducing an
allergic type of response to parasitic destruction [11,13,56].
This paradoxical reaction occurs in approximately 50% of
patients treated for AS with praziquantel [8,11,56]. In some
cases, this worsening of symptoms can be life-threatening by
causing encephalitis related to vasculitis [29], myocarditis
[45], or pulmonary events [49].
Considering that the pathophysiological mechanisms of AS
result more from the immunological response to larvae
migration than to the parasitic location, more and more
authors recommend the use of corticosteroids
[11,13,14,18,25,42,57]. According to them, praziquantel is
used either in combination with corticosteroids [14,15,57]
or following corticosteroid treatment [17,58]. Others,
including ourselves, wait for egg-laying before using praziqu-
antel [13,18]. It is of note that the use of corticosteroids
decreases plasma levels of praziquantel by 50% [59]. Praziqu-
antel needs a good host-speciﬁc response against Schistosoma
to be efﬁcient [26,53]. During the early stage of AS, the
weakness of the speciﬁc immune response might explain why
praziquantel is not effective at this stage [52]. Overall, the
use of corticosteroids is discussed on a case-by-case basis
after ruling out bacterial infection and strongyloı¨dosis [8,60].
Relapses of AS have also been described [8,61]. Relapsing
forms, which occur after a median time period of 15 days
after the end of the primary symptomatically similar episode,
are treated with praziquantel and/or corticosteroids in an
unknown proportion of patients [8,61].
Oxamniquine, arthemeter, and combined treatment
Oxamniquine (50 mg/kg once) could be indicated at the early
phase of schistosomiasis, because it is more efﬁcient against
schistosomulae than praziquantel. Nonetheless, it is efﬁcient
only in the case of S. mansoni infection. When prescribed
during the early stage (ﬁrst week) of the infection or during
AS, it prevents the occurrence of chronic S. mansoni infec-
tion and egg-laying [26,62,63].
Arthemeter, an artemisin derivative, is also efﬁcient
against schistosomulae aged 7–21 days [52]. In one compara-
tive trial performed in the Coˆte d’Ivoire, arthemeter reduced
the incidence of S. mansoni infection by 50% in exposed chil-
dren [64]. Moreover, a 60–100% protective effect has been
suggested in a Chinese population exposed to S. japonicum
[65]. A double-blind study comparing oral arthemeter and
placebo in 322 exposed children in the Coˆte d’Ivoire showed
a decrease in the incidence rate of S. haematobium by 65% as
compared with 49% in the placebo group [66].
Combined therapy should also be considered [53]. A
combination of arthemeter and praziquantel showed a 99%
reduction in egg burden, as compared with a 94% reduction
with the use of praziquantel alone, in 88 and 89 children,
respectively, treated in Gabon [67]. Other antimalarial drugs,
such as meﬂoquine, seem to have an antischistosomidae
effect on mice [26,68].
Prevention
Obviously, the best way to prevent AS is to avoid exposure to
contaminated water in endemic areas. Otherwise, many topi-
cal ointments have been evaluated to protect swimmers from
cercarial dermatitis. With the exception of N,N-diethyl-m-tol-
uamide 50% ointment, none have given promising results;
the use of sunscreens, copper salt, niclosamide, dimethyl
phthalate-based or butylacetylaminopropionate-based oint-
ments did not protect against Schistosoma infection [69]. The
use of petroleum jelly and vigorous drying with towels, with
application of ethanol to exposed skin, has been proposed as
an effective means of reducing cercarial penetration, but no
study has demonstrated the effectiveness of this procedure
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[25,61]. In contrast, the use of N,N-diethyl-m-toluamide 50%
ointment in 15 travellers at Lake Malawi was associated with
the absence of infection during a 3-month follow-up period
[70]. Prior to being used for personal cleaning, contaminated
water should be heated to 50C for 5 min or treated with
iodine or chlorine. Water can also be ﬁltered with paper ﬁlters
or left standing for 3 days before use [61].
Conclusion
The diagnosis and treatment of AS remains a challenge. Diag-
nosis relies mainly on positive serological testing. Treatment
is based on corticosteroids in severe forms, and praziquantel
should be initiated only when ova are detected in stools or
urine, depending on the culprit species. Early treatment with
oxamniquine (in the case of S. mansoni infection) or artheme-
ter shows promise and should now be evaluated in exposed
travellers.
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